CRISPR-Cas systems are efficient and easily programmable nucleic acid-targeting tools, with usage expanding beyond research and therapeutic development to precision breeding of plants and animals and engineering of industrial microbes. CRISPR-Cas systems have potential applications in microbial engineering including bacterial strain typing, immunization of cultures, autoimmunity or self-targeted cell killing, and the engineering or control of metabolic pathways for improved biochemical synthesis. The global CRISPR and Cas genes market was valued at US$ 1,451.6 Mn in 2017 and is anticipated to reach US$ 7,234.5 Mn by 2026, expanding at a CAGR of 20.1% from 2018 to 2026.
Usage of CRISPR-Cas systems in bacteria, rise in government spending on research and development of genome editing, increase in incidence of genetic disorders, and usage of CRISPR/Cas9 technology to improve crop production drive the global CRISPR and Cas genes market. Genome editing technologies such as CRISPR/Cas9 is a revolutionary step in the field of biomedical research. Application of CRISPR/Cas9 focusing on somatic cell genome editing program is aimed at accelerating the use of these technologies to treat various genetic disorders. However, ethical issues concerning CRISPR and lack of skilled professionals restrain the global CRISPR and Cas genes market.
Based on region, North America and Europe dominated the global CRISPR and Cas genes market in 2017, accounting for 71% share. Rise in research activities and technological advancements are expected to drive the CRISPR and Cas genes market in the regions during the forecast period. In 2016, a human clinical trial was initiated for the use of CRISPR to treat diseases in the U.S. Increase in adoption of technology and presence of key players in the region are likely to accelerate the growth of the CRISPR and Cas genes market in Europe during the forecast period.
Perceive the Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26417
Major players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. These players adopt organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and capture market share.